New drug combo aims to stop head and neck cancer from returning

NCT ID NCT01783587

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Mar 25, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This early-phase study tested the safety of adding the drug afatinib to standard radiation therapy (with or without chemotherapy) for people with intermediate- or high-risk head and neck cancer after surgery. Afatinib blocks proteins that help cancer grow and may make cancer cells more sensitive to radiation. The goal was to find the safest dose and see if the combination could reduce the chance of cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02115, United States
Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Conditions

Explore the condition pages connected to this study.

SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK